BackScopus Biopharma Overview

Scopus Biopharma Minority Interest

Latest minority interest for SCPS: $-1.1M.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$-1.05M

Peer average

Loading

Scopus Biopharma Minority Interest History

Loading

Scopus Biopharma vs. peers: Minority Interest Comparison

Loading

Scopus Biopharma Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Scopus Biopharma (SCPS) FAQ

As of the most recent data (June 2023), SCPS shows a minority interest of $-1.1M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SCPS's minority interest is now $-1.1M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Scopus Biopharma is outperforming or lagging.

Tracking SCPS's minority interest over time shows whether Scopus Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-1.1M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has Scopus Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $-1.1M) with ownership activity and broader fundamentals.

Scopus Biopharma's minority interest is $-1.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.